30 closest matches · ranked by relevance
Ampulla of Vater Adenocarcinoma · Small Intestinal Adenocarcinoma · Stage III Ampulla of Vater Cancer AJCC v8
Primary: Number of Participants With Progression-free Survival (PFS) at Six Months — 68 percentage of participants
Gastrointestinal Cancer
Primary: Number of Participants With Overall Response — 3; 12 participants
Pancreatic Cancer Non-resectable · Pancreatic Cancer Metastatic
Primary: Disease Control Rate (DCR) at 4 Months Using RECIST 1.1 — 2 Participants
Gastrointestinal Cancer
Primary: Response Rate (RR) — 19 Participants
Adenomatous Polyps
Primary: Percent of Incompletely Resected Adenomatous Polyps — 10.1 percentage of incomplete resection
Pancreatic Adenocarcinoma
Primary: The Concentration of the Pancreatic Cancer Markers of the Normal Cohort and UICC Stage II Pancreatic Ductal Adenocarcinoma Cohort — 99097; 34095 pg/ml — p=<0.001
Colorectal Cancer · Cancer of Gastrointestinal Tract
Primary: Response Rate in CIMP-High Colorectal Cancer and Small Bowel Adenocarcinoma (SBA) — 0; 0; 0; 2 Participants
Colorectal Adenomatous Polyps
Primary: Number of Participants With Conventional Adenoma and Sessile Serrated Adenoma/Polyp Detected — 208; 171 Participants
Small Bowel Cancers · Colorectal Cancers
Primary: Objective Response Rate (ORR) for Triple Therapy — 0; 0 Proportion of participants
Familial Adenomatous Polyposis
Primary: Number of Polyps — 18.6; 22.6 Number of Polyps
Pancreatic Adenocarcinoma
Primary: Number of Subjects Completing Therapy Including Surgical Resection. — 107 Participants
Esophageal Cancer
Primary: Response Rate (RR) — 6 percentage of participants
Pancreatic Cancer
Primary: Overall Survival — 24.8 Months
Adenosquamous Carcinoma of the Pancreas
Primary: Proportion of Evaluable Participants Who Experience Clinical Benefit (Disease Control Rate = Complete Response (CR)+Partial Response (PR)+Stable Disease x16 Weeks)…
Risk for Colorectal Cancer
Primary: Number of Participants With Anti Muc-1 Antibody — 39 participants
Biliary Cancer · Cholangiocarcinoma
Primary: Progression Free Survival Rate at Five Months — 69 percentage of participants
Small Intestine Adenocarcinoma · Recurrent Small Intestine Cancer
Primary: Confirmed Tumor Response Rate (Proportion of Participants With Complete Response) — .38 proportion of patients
Gastrointestinal and Gynecologic Malignancies
Primary: Rate of Detectable Peritoneal Metastases — 0; 2 percentage of lesions
Pancreatic Neoplasms
Primary: Acute Toxicity Rates of Grade 3 or Greater Gastrointestinal and Hematologic Toxicities (as Raw Percentage) — 13.89; 0.00; 2.78; 0.00 percentage of participants
Pancreatic Endocrine Neoplasms
Primary: Nonfunctioning and Malignant Pancreatic Endocrine Neoplasms — 28; 12; 22; 18 participants
Adenomatous Polyp · Recurrent Colon Cancer · Recurrent Rectal Cancer
Primary: Change in ACF pERK Levels
Locally Advanced Pancreatic Adenocarcinoma
Primary: Number of Subjects With Treatment Emergent Adverse Events (Safety and Tolerability) — 3; 3; 4; 23 Participants
Adrenocortical Carcinoma · Peritoneal Carcinomatosis
Primary: Intraperitoneal Progression Free Survival (PFS) — 19 Months
Colorectal Neoplasms · Peritoneal Neoplasms
Primary: Peritoneal Recurrence Free Survival at 18 Months — 79; 80 participants
Peritoneal Carcinomatosis · Colorectal Cancer · Appendiceal Cancer
Primary: Completeness of Cytoreduction
Cancer of Rectum · Cancer of the Rectum · Neoplasm, Rectum
Primary: Complete Response Rate — 12 Participants
Adult Primary Cholangiocellular Carcinoma · Advanced Adult Primary Liver Cancer · Cholangiocarcinoma of the Extrahepatic Bile Duct
Primary: Overall Survival — 4.7; 1.6; 3.94 months
Gastric Cancer · Adenocarcinoma
Primary: Overall Survival (OS) — 5.2; 3.8 months — p=0.0473
Metastatic Pancreatic Cancer
Primary: Progression Free Survival With the Combination of GDC-0449 With Gemcitabine and Nab-paclitaxel. — 5.42 months
Spondyloarthritis · Enterocolitis
Primary: Change Lewis Score Index — -225 units on a scale